Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma (IMMUNO-TH)
Sponsor: Assistance Publique - Hôpitaux de Paris
A PHASE2 clinical study on Hepatocellular Carcinoma Recurrent and Liver Transplant, this trial is actively recruiting participants. The trial is conducted by Assistance Publique - Hôpitaux de Paris and has accumulated 5 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2026 — Mar 2026 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2024 — Jan 2026 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
For direct contact, visit the study record on ClinicalTrials.gov .